JNJ

228.67

+0.94%↑

UNH

388.28

+1.06%↑

TMO

440.08

+1.36%↑

ISRG

436.67

+3.24%↑

ABT

87.65

+3.07%↑

JNJ

228.67

+0.94%↑

UNH

388.28

+1.06%↑

TMO

440.08

+1.36%↑

ISRG

436.67

+3.24%↑

ABT

87.65

+3.07%↑

JNJ

228.67

+0.94%↑

UNH

388.28

+1.06%↑

TMO

440.08

+1.36%↑

ISRG

436.67

+3.24%↑

ABT

87.65

+3.07%↑

JNJ

228.67

+0.94%↑

UNH

388.28

+1.06%↑

TMO

440.08

+1.36%↑

ISRG

436.67

+3.24%↑

ABT

87.65

+3.07%↑

JNJ

228.67

+0.94%↑

UNH

388.28

+1.06%↑

TMO

440.08

+1.36%↑

ISRG

436.67

+3.24%↑

ABT

87.65

+3.07%↑

Home・Akciju saraksts・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

14.49 0.21

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.49

Max

14.49

Galvenie mērījumi
By Trading Economics
Ienākumi	-16M 1.7M
Pārdošana	16M 185M
Peļņas marža	0.912
Darbinieki	511
EBITDA	-31M 16M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	61M 4.5B
Iepriekšējā atvēršanas cena	14.28
Iepriekšējā slēgšanas cena	14.49

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

5.925 / 7.38 Atbalsts un pretestība

Amicus Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. apr. 23:08 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 23:07 UTC

Peļņas

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:20 UTC

Peļņas

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 23:48 UTC

Tirgus saruna

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026. g. 30. apr. 23:27 UTC

Tirgus saruna

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026. g. 30. apr. 23:22 UTC

Peļņas

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026. g. 30. apr. 23:20 UTC

Tirgus saruna

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026. g. 30. apr. 22:52 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:33 UTC

Peļņas

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026. g. 30. apr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026. g. 30. apr. 22:05 UTC

Peļņas

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 21:57 UTC

Peļņas

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026. g. 30. apr. 21:55 UTC

Peļņas

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026. g. 30. apr. 21:53 UTC

Peļņas

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Salīdzinājums

Cenas izmaiņa

Amicus Therapeutics Inc Prognoze

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Amicus Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

5.925 / 7.38Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanšu rādītāji

Par Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.